Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2024 Oct 25;15:1497520. doi: 10.3389/fphar.2024.1497520

Corrigendum: CHF6297: a novel potent and selective p38 MAPK inhibitor with robust anti-inflammatory activity and suitable for inhaled pulmonary administration as dry powder

Cataldo Martucci 1, Andrew Dennis Allen 1, Nadia Moretto 1, Valentina Bagnacani 1, Alessandro Fioni 1, Riccardo Patacchini 1, Maurizio Civelli 1, Gino Villetti 1, Fabrizio Facchinetti 1,*
PMCID: PMC11544349  PMID: 39525638

In the published article, there was an error in Figure 1 as published. The chemical structures described in Figure 1 were inaccurate. The corrected Figure 1 and its caption appear below.

FIGURE 1.

FIGURE 1

Chemical structures of the p38α inhibitors CHF6297, losmapimod, and AZD7624.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES